TRML - NASDAQ

Tourmaline Bio, Inc.

TRML·NASDAQ

$47.98

+0.0000%

HealthcareBiotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.23B

EPS-2.8900

P/E Ratio-7.02

Earnings Date04/30/2026

-77.26M

Operating Cash Flow

175%

3Y+93.0%

5Y+338.0%

10Y+338.0%

-194.31M

Investing Cash Flow

-5160%

3Y+102.0%

5Y+34474.0%

10Y+34474.0%

161.35M

Financing Cash Flow

3Y+17.0%

5Y+346.0%

10Y+346.0%

Tourmaline Bio, Inc. Cash Conversion Engine

TRML · NASDAQ

FCF Components

Net Income-73.21M

Depreciation & Amortization39.00K

Stock-Based Compensation6.59M

Change in Working Capital-3.15M

Others-7.53M

Capital Expenditures-9.00K

Free Cash Flow-77.27M

Cash Flow Quality Analysis

FCF Conversion Rate

105.5%

Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.

CapEx Intensity

-0.0%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

-174.6%

Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.

Working Capital Impact

-$3.15M

Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.

Cash Flow Quality Insight

Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.

Tourmaline Bio, Inc. Cash Flow Statement

TRML • NASDAQ

Tourmaline Bio, Inc. Cash Flow Statement	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
OPERATING ACTIVITIES
Net Income	-73.2M	-42.1M	-19.7M	-47.8M	-22.7M	-18.2M
Depreciation & Amortization	39K	33K	6K	623K	447K	379K
Stock-Based Compensation	6.6M	5.8M	195K	0.0	0.0	0.0
Other Non-Cash Items	-7.5M	8.4M	12.1M	4.9M	1.4M	201K
Change in Working Capital	-3.2M	-168K	902K	2.3M	1.6M	-85K
Cash from Operating Activities	-77.3M	-28.1M	-6.5M	-40M	-19.2M	-17.7M
INVESTING ACTIVITIES
Investments in Property, Plant, and Equipment	-9K	-56K	-68K	-2.4M	-1.3M	-562K
Acquisitions, Net	(0.0)	(0.0)	-5M	(0.0)	(0.0)	(0.0)
Purchase of Investments	-366.1M	-16.6M	(0.0)	-275.9M	-158.2M	(0.0)
Sale/Maturity of Investments	171.8M	20.5M	0.0	181.9M	26.2M	0.0
Other Investing Items	0.0	0.0	0.0	0.0	-1K	0.0
Cash from Investing Activities	-194.3M	(3.8M)	-5.1M	-96.4M	-133.3M	-562K
FINANCING ACTIVITIES
Net Issuance of Common Stock	161.4M	70.5M	20M	137.7M	131.1M	36.2M
Net Issuance of Debt	0.0	0.0	-150K	0.0	0.0	0.0
Other Financing Items	-4K	-5.6M	0.0	-277K	0.0	0.0
Cash from Financing Activities	161.3M	156.7M	19.9M	137.4M	131.1M	36.2M
CASH FLOW SUMMARY
Net Change in Cash	-110.2M	132.5M	8.3M	1M	-21.4M	18M
Cash at Beginning of Period	141M	8.5M	150K	17.6M	39M	21M
Cash at End of Period	30.7M	141M	8.5M	18.6M	17.6M	39M
Free Cash Flow	-77.3M	-28.1M	-11.5M	-42.4M	-20.5M	-18.2M

SEC Filings

TRML - Filing history and reports

No SEC filings available for TRML

Related Guides

Blog Categories

Continue your TRML research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.